Williams & Connolly client Pfizer secured a win before the Federal Circuit in IPR proceedings initiated by Pfizer against uniQure biopharma B.V. concerning patents generally related to gene therapy for hemophilia B. In 2022, after deciding to institute trial, the PTAB ruled in Pfizer’s favor, invalidating all claims of the challenged patents. And on May 22, 2025, following oral argument by Dov Grossman, the Federal Circuit affirmed, upholding the Board’s decision that all of the challenged claims are unpatentable.
In addition to Dov, the Pfizer team included David Berl, Shaun Mahaffy, Kat Kayali, and Michael Liu.
To read Law360’s coverage of the case, click here.